Stock Price & Analysis

Based on the provided data and recent market activity, here's a comprehensive analysis of JNJ stock:

Technical Analysis

The stock is showing positive momentum, with JNJ closing at $162.30 on February 21, 2025, representing a +1.64% gain during regular market hours. The stock has established a support level around $159 and resistance near $163.50 based on recent trading patterns.

Fundamental Strengths

• Strong market position as the world's largest healthcare company
• AAA credit rating from S&P (highest available)
• 62-year track record of consecutive dividend increases
• Robust pipeline with nearly 100 ongoing programs

Recent Catalysts

1. TREMFYA Trial Success:

• Latest clinical trial met primary and secondary goals for ulcerative colitis treatment
• Stock responded positively with a 1% increase in premarket trading

2. Strategic Acquisition:

• $14.6 billion acquisition of Intra-Cellular Therapies announced
• Strengthens neurological business portfolio long-term

Market Performance

• YTD Return: +5% (outperforming S&P 500's 1.9%)
• 52-week performance: -3% (underperforming S&P 500's +20.9%)

Analyst Consensus

• Rating: "Moderate Buy" based on 22 analysts
• 8 Strong Buy, 2 Moderate Buy, 12 Hold ratings
• Mean price target: $169.45 (11.6% upside potential)
• Street-high target: $190 (25.1% upside potential)

Buy Recommendation

Based on the analysis, JNJ presents a compelling buying opportunity at current levels due to:

• Strong fundamental business position
• Recent positive clinical trial results
• Strategic acquisition to enhance growth
• Attractive valuation with meaningful upside potential
• Defensive characteristics and reliable dividend growth

Based on the provided data and recent market developments, here is my price prediction analysis for JNJ stock in 2025:

Technical Analysis

The technical indicators show JNJ is currently in a bullish trend with strong momentum:

• RSI(14) at 71.58 indicates slightly overbought conditions
• MACD is positive with bullish crossover (MACD: 2.94, Signal: 2.32)
• Price trading above all major moving averages (SMA 20: $154.34, SMA 200: $152.94)

Fundamental Drivers

Key catalysts supporting higher prices in 2025:

• Strong Q4 2024 results with revenue of $22.5B (+5.3% YoY)
• Management guidance for 2025 EPS growth of 5-6% to $10.50-$10.70
• Strategic acquisition of Intra-Cellular Therapies for $14.6B strengthening neurology portfolio
• Improved business focus after Kenvue spinoff

Price Target Analysis

Based on the technical setup and fundamental outlook, I project JNJ stock to reach $175-180 by end of 2025, representing ~10-12% upside from current levels. This target is supported by:

• Mean analyst price target of $169.45 with high target of $190
• Forward P/E of 25.05x on 2025 EPS guidance suggests room for multiple expansion
• Strong free cash flow generation projected at over $23B for 2025

The key risks to monitor are patent expiration of Stelara and ongoing talc litigation cases.

The S1 support level for JNJ Stock is $155.01 ,The R1 resistant level for JNJ Stock is $165.09.

As of the end of day on 2025-02-28, the price of JNJ Stock was $163.54.

The target price for JNJ Stock according to analyst rating is 167.50, with the highest price target at 185.00 and the lowest at 152.00. Analysts have a Moderate Buy rating on JNJ Stock overall.

The market cap of JNJ is $394.2B.

Based on the comprehensive financial data and market analysis, JNJ appears to be fairly valued rather than overvalued at current levels. Here's why:

Valuation Metrics Show Reasonable Levels

• Current P/E of 30.12x is higher than historical average but justified given the company's strong market position and consistent growth
• EV/EBITDA of 12.24x is actually below the 5-year average, indicating attractive valuation from an operational perspective
• Price/Sales ratio of 4.71x reflects the company's premium positioning but has declined from previous years

Strong Financial Performance

• Revenue grew to $85.16B in 2023, showing steady growth trajectory
• Gross margins remain robust at 69.18%, demonstrating pricing power
• Current ratio of 1.16x indicates healthy liquidity position
• Debt-to-equity ratio improved to 42.65% from 51.64% in 2022

Technical Indicators Support Current Valuation

• RSI at 71.58 suggests slightly overbought conditions but not extreme
• Stock trading above key moving averages (SMA 20, 60, 200)
• Bollinger Band analysis shows price near upper band but within normal range

Recent Developments Support Valuation

• Successful acquisition of Intra-Cellular for $14.6B strengthens neuroscience portfolio
• Positive results from TREMFYA late-stage trial for ulcerative colitis
• Strong market position as 9th best-performing Dow stock in 2025 with 8.42% YTD return

The stock's current valuation appears justified given JNJ's market leadership, strong financials, and growth initiatives, though it's approaching the upper end of its fair value range.

Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, interventional solutions, and vision fields. These products are distributed to wholesalers, hospitals, and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics.

Based on the provided data and market research, here's a detailed analysis for JNJ's price prediction in 2030:

Market Position and Growth Trajectory According to recent analysis, Johnson & Johnson ranks 9th among the best-performing Dow stocks in 2025, with a year-to-date return of 8.42%. The company has shifted its focus to growth through strategic acquisitions after spinning off its consumer health business.

Growth Catalysts Through 2030

• The company projects annual growth rate between 5% and 7% from 2025 through 2030
• Multiple myeloma market expected to reach $33 billion by 2030, with JNJ positioned to capture significant market share
• Darzalex sales projected to hit $14.7 billion by 2030

Price Target 2030: $275-285 The stock is expected to reach approximately $280 by 2030, driven by:

• Consistent 5-7% annual revenue growth projection
• Strong position in multiple myeloma market
• Strategic acquisitions like Intra-Cellular ($14.6 billion) strengthening neurological business

JNJ has a total of 131900 employees.